Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218787 · ClinicalTrials.gov registry record · NA
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,047
- Enrollment target
NCT03218787 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,047 participants.
The verdict
NCT03218787, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,047 participants
- Enrollment target
Study Summary
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting stents. The XIENCE family stent systems include commercially approved XIENCE Xpedition Everolimus Eluting Coronary Stent System (EECSS), XIENCE Alpine EECSS, XIENCE PRO\^X EECSS \[rebrand of the XIENCE Xpedition Stent System and is only available outside of the United States (OUS)\], XIENCE PRO\^A EECSS (rebrand of the XIENCE Alpine Stent System and is only available OUS) and XIENCE Sierra EECSS of coronary drug-eluting stents.
Interventions
- DEVICE XIENCE
- DRUG DAPT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,047 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2020-09-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03218787
The ClinicalTrials.gov registry entry for NCT03218787 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2,047 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT03218787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03218787 about?
NCT03218787 is a clinical study titled "XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.". XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting sten...
What is the current status of trial NCT03218787?
This trial is currently completed. It is a NA study. The enrollment target is 2,047 participants. The study started on 2017-07-19. Estimated completion is 2020-09-04.
What interventions are being tested in trial NCT03218787?
The interventions under investigation include: XIENCE (DEVICE), DAPT (DRUG).
Who is sponsoring clinical trial NCT03218787?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.